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Background: The development of ascites in cirrhotic patients generally heralds a deterioration in their clinical
status. A differential gene expression profile between alcohol- and hepatitis C virus (HCV)-related cirrhosis has been
described from liver biopsies, especially those associated with innate immune responses. The aim of this work was
to identify functional differences in the inflammatory profile of monocyte-derived macrophages from ascites in
cirrhotic patients of different etiologies in an attempt to extrapolate studies from liver biopsies to immune cells in
ascites. To this end 45 patients with cirrhosis and non-infected ascites, distributed according to disease etiology,
HCV (n = 15) or alcohol (n = 30) were studied. Cytokines and the cell content in ascites were assessed by ELISA and
flow cytometry, respectively. Cytokines and ERK phosphorylation in peritoneal monocyte-derived macrophages
isolated and stimulated in vitro were also determined.
Results: A different pattern of leukocyte migration to the peritoneal cavity and differences in the primed status of
macrophages in cirrhosis were observed depending on the viral or alcoholic etiology. Whereas no differences in
peripheral blood cell subpopulations could be observed, T lymphocyte, monocyte and polymorphonuclear cell
populations in ascites were more abundant in the HCV than the alcohol etiology. HCV-related cirrhosis etiology was
associated with a decreased inflammatory profile in ascites compared with the alcoholic etiology. Higher levels of
IL-10 and lower levels of IL-6 and IL-12 were observed in ascitic fluid from the HCV group. Isolated peritoneal
monocyte-derived macrophages maintained their primed status in vitro throughout the 24 h culture period. The
level of ERK1/2 phosphorylation was higher in ALC peritoneal macrophages at baseline than in HCV patients,
although the addition of LPS induced a greater increase in ERK1/2 phosphorylation in HCV than in ALC patients.
Conclusions: The macrophage inflammatory status is higher in ascites of alcohol-related cirrhotic patients than in
HCV-related patients, which could be related with differences in bacterial translocation episodes or regulatory T cell
populations. These findings should contribute to identifying potential prognostic and/or therapeutic targets for
chronic liver diseases of different etiology.
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Alcoholic liver disease (ALD) and hepatitis C virus (HCV)
infection are the two major causes of chronic liver diseases
in the developed world [1]. The development of ascites, an
accumulation of fluid in the peritoneal cavity, in a cirrhotic
patient generally runs parallel with deterioration in clinical
status and presages a poor prognosis. While the overall cir-
rhosis mortality rate has falling in the last three decades [2],
HCV mortality rates, closely associated with cirrhosis, have
been increasing since the 1990s [3]. For the clinical man-
agement of cirrhosis, it is important to assess whether the
differences in the outcomes of cirrhosis depend on the eti-
ology. In this respect, the histopathology of alcohol-induced
cirrhosis (ALC-C) and HCV-induced cirrhosis (HCV-C) is
very similar and characteristic fibrosis patterns leading to
cirrhosis can overlap in them [4]. Nonetheless, little is
known regarding the differences and/or similarities be-
tween alcohol- and HCV- induced liver disease at the mo-
lecular level [5] and, to the best of our knowledge, no data
on human peritoneal cells have bee reported.
Global transcriptional profiling using oligonucleotide
microarrays on liver biopsies from patients with cirrhosis
showed that some genes are differentially expressed be-
tween ALC-C and HCV-C. Many of the gene expression
changes specifically observed in HCV-induced cirrhotic
livers were related to activation of the innate antiviral im-
mune response, while differential mechanisms between
chronic liver damage due to HCV or ethanol may be
related to regulation of the lipid metabolism and macro-
phage activation resulting in the deposition of extracellular
matrix components [1,5]. Additionally, several studies have
demonstrated that alcohol exposure activates innate im-
munity and induces several pro-inflammatory cytokines, in-
cluding TNF-α, subsequently inducing hepatocellular
damage. The activation of innate immunity also results in
higher levels of hepatoprotective intermediaries, such as IL-
6, and anti-inflammatory cytokines, such as IL-10, which
play an important role in ameliorating alcoholic liver injury
and inflammation [6]. However, chronic alcohol exposure
attenuates the signaling pathways triggered by these cyto-
kines, thereby limiting their anti-inflammatory and hepato-
protective effects, and contributing to the development of
ALD [7].
Monocyte-derived macrophages (M-DM) play an import-
ant role as antigen-presenting cells of the innate immune
response established against pathogen associated molecular
patterns (PAMPs), including bactDNA and LPS [8]. In this
respect, we reported bactDNA-activated cell-mediated im-
mune response and nitric oxide overproduction through
the inducible form of NO synthase in peritoneal macro-
phages from patients with cirrhosis and ascites [9] and,
more recently, the primed status of peritoneal M-DM from
cirrhotic patients related to ERK phosphorylation and IL-6
secretion [10].This study focuses on the inflammatory profile of asci-
tes and peritoneal M-DM from patients with ALC-C or
HCV-C to assess whether the immune status and in-
flammatory mechanisms leading to end-stage liver cir-
rhosis present a different pattern, depending on the
agent that caused this pathology, and extrapolate out
from previous studies performed in liver biopsies to im-
mune cells in ascites.Results
Patient baseline characteristics
A consecutive series of 61 patients with cirrhosis and as-
cites was initially recruited for the study. Sixteen patients
were excluded due to episodes of gastrointestinal bleed-
ing in the previous 2 weeks (n = 2), culture-positive asci-
tes (n = 3), hepatocellular carcinoma (n = 2), mixed
alcoholic and viral etiology (n = 4), hepatitis B virus in-
fection etiology (n = 1) or continuous use of norfloxacin
as secondary prophylaxis of spontaneous bacterial peri-
tonitis (n = 4). Finally 45 patients fulfilling all the inclu-
sion criteria were included in the study, distributed
according to disease etiology, HCV-C (n = 15) or ALC-C
(n = 30). The clinical and analytical characteristics of
patients are detailed in Table 1. Blood and ascites cul-
tures were negative in all cases. None of the patients
died during hospitalization or developed spontaneous
bacterial peritonitis.
As can be observed from Table 1, the absolute total
number of ascitic leukocytes found in patients with
HCV-C was significantly higher than in ALC-C patients.
These differences were not detected in blood.
There were no significant differences as regards the
rest of the clinical and analytical characteristics between
the two groups of patients studied.
During 6-month follow-up study, three patients from
the ALC-C group and one patient from the HCV-C
group died. The causes of death in the ALC-C group
were liver insufficiency (n = 2) and renal failure (n = 1).
In the HCV-C group, the cause of death was renal fail-
ure (n = 1).HCV-C is associated with increased counts of some
leukocyte subpopulations in ascites
To further explore differences in the number of leuko-
cytes present in the ascites of both groups, the leukocyte
subpopulations were characterized by flow cytometry
analysis based on both the morphology and CD receptor
expression criteria. The results presented in Table 2
show that T lymphocytes, PMNs and M-DM counts
were high in the ascites of HCV-C patients compared
with the ALC-C group. A study of subset cell type distri-
bution in blood showed no significant differences be-
tween ALC-C and HCV-C patients (data not shown).
Table 1 Clinical and analytical characteristics of patients
included in the study
Variable Patients with cirrhosis and
culture-negative ascites (n = 45)
Etiology ALC-C (30) HCV-C (15)
Age 58.5 (12.5) 58 (24)
Male sex n (%) 30 (100.0) 14 (93.3)
Previous episodes of ascites n (%) 25 (83.3) 13 (86.6)
Child-Pugh mean score 10 (3) 9 (3)
Meld mean score 14.5 (10) 14 (5)
Bilirubin (mg/dl) 2.7 (3) 1.85 (1.7)
Albumin (g/dl) 2.9 (1.1) 2.85 (0.9)
Quick (%) 64 (18) 54 (24)
Serum creatinine (mg/dl) 1.07 (1.2) 1 (0.5)
Serum sodium (mEq/l) 134 (6.3) 136 (7)
INR 1.45 (0.3) 1.46 (0.6)
Blood WBC/mm3 4260 (2400) 3930 (4040)
Ascites WBC/mm3 21.29 (47.4) 49 (82.8)*
Ascites Total protein (g/dl) 1.7 (0.3) 1.6 (1)
Continuous variables are expressed as median (interquartile range) and
categorical variables as percentage. WBC: white blood cells; Mann–Whitney U test
* P < 0.05.
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inflammatory levels are lower in the ascites of HCV-C
cirrhotic patients
Figure 1 shows the concentration in pg/ml of IL-10, IL-
12, IL-1β, IL-6 and TNF-α. The results showed that the
ascites from the HCV-C group had lower levels of pro-
inflammatory cytokines, although the differences be-
tween both groups were statistically significant only in
the case of IL-12. The results also revealed that IL-10
anti-inflammatory cytokine levels in the ascites of HCV-
C patients were significantly higher than the correspond-
ing levels from the ALC-C group of cirrhotic patients.
Peritoneal M-DM isolated from ascites of cirrhotic
patients maintain their cytokine secretory profile in vitro
We next compared the cytokine production ability of
the peritoneal M-DM from HCV-C and ALC-C patients,Table 2 White blood cell distribution in ascites
Etiology
Cell type/mm3 ALC-C HCV-C
PMNs 0.5 (4.4) 3.4 (7)*
M-DM 6.95 (12.6) 14.8 (19.9)*
T Lymphocytes 7.37 (12.6) 14,66 (22.6)*
B Lymphocytes 0.16 (0.5) 0.21 (0.3)
NK cells 1.22 (2.2) 2.01 (5.6)
Results are expressed as median (interquartile range). Mann–Whitney U test:
* P < 0.05.first exploring the relative contribution of the M-DM to
the cytokines contained in ascites by referring the con-
centration of cytokines to the number of this cell type
(Figure 2A). Then we analyzed the basal production of
cytokines in 24 h cultures of the M-DM population iso-
lated from ascites (Figure 2B).
The results revealed that M-DM from the HCV-C
group produces significantly lower levels of IL-12, but
also of IL-6 and TNF-α cytokines, than the ALC-C
group when M-DM were isolated and cultured in vitro
(Figure 2B). These data are consistent with those of
cytokine levels in the ascites (Figure 2A), indicating that
M-DM are “primed” by the pathological microenviron-
ment and preserve their secretory profile, being more
pro-inflammatory in the case of ALC-C group.
No significant differences in IL-10 production were
observed between the two groups as regards a M-DM
cultured in vitro, nor with respect to M-DM present in
ascites, indicating that M-DM are not the main cell type
responsible for the differences found for this cytokine in
ascites.
Peritoneal M-DM isolated from ascites of cirrhotic
patients are able to further respond to in vitro stimulation
with several microbial stimuli
Spontaneous bacterial peritonitis (SBP) caused by the
translocation of intestinal bacteria and their products,
such as LPS or bacterial DNA, is one of the main life-
threatening complications of cirrhosis. Given this, the
quality and intensity of the peritoneal immune response
plays a crucial role in the prognosis of these compro-
mised patients. To seek further insight into the ability of
cirrhotic peritoneal M-DM to respond to different
PAMPs, we studied the capability of isolated M-DM to
respond to LPS, synthetic CpG-ODNs and heat-killed C.
albicans as examples of stimuli able to trigger activation
and phagocytosis through different PRRs. For this pur-
pose, the cytokines produced by M-DM cultured for
24 h in the presence of these stimuli were studied. The
results shown in Table 3 reveal that this cell population
is able to further recognize and respond to different
PAMPs, although significant differences were observed,
depending on the cytokine in question and the specific
stimuli applied. The results shown in Table 3 point to a,
first strong significant response of TNF-α secretion in
the presence of LPS and C. albicans in M-DM from
both groups of patients. Second, IL-6 and IL-10 secre-
tion was significantly increased in all stimulatory condi-
tions, except in the M-DM from ALC-C patients after
stimulation by ODN. Third, the relative increases in IL-6
was significantly higher in HCV-C for the three stimuli
assayed, while the increase in IL-10 secretion was only
significant in the ALC-C group stimulated by ODN.
Fourth, secreted IL-12 was only significantly increased
Figure 1 Levels of pro- and anti-inflammatory cytokines in ascites from patients with HCV-C or ALC-C. Cytokine concentration was
measured by ELISA in ascites from patients with HCV-C (n = 15) or ALC-C (n = 30). Results are expressed in pg/ml and represented as box plot.
Circles out of the boxes correspond to outliers. The median and IQR are indicated for each box. Mann–Whitney U test: * P < 0.05, ** P < 0.01.
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patients. Finally, LPS and C. albicans induced a signifi-
cant increase in secreted IL-1β in M-DM from both
groups of patients compared with their respective con-
trols, although no significant differences were observed
between groups.
ERK1/2 phosphorylation levels are lower in peritoneal M-
DM isolated from ascites of patients with HCV-C vs. ALC-C
We recently described the primed status of peritoneal
macrophages in cirrhosis, finding it to be related to
ERK1/2 phosphorylation and IL-6 secretion [10]. We
therefore further analyzed the phosphorylation of ERK1/
2 at baseline and in the presence of LPS in M-DM from
both group of patients. As shown in Figure 3, the results
confirmed the primed status of ERK1/2 phosphorylation
in peritoneal M-DM from ALC-C patients, which is con-
sistent with the high concentration of IL-6 with respect
to M-DM in ALC-C ascites, as well as with the IL-6
level produced in vitro by isolated M-DM cells from
ALC-C patients. In contrast, baseline phosphorylation of
ERK1/2 in M-DM from HVC-C patients was very low,
although its relative increase after exposure to LPS for15 min was higher than the corresponding increase in
M-DM from ALC-C group. Again, this observation is
consistent with the relative increase of IL-6 after LPS
stimulation described above. These results confirm and
extend the positive correlation previously established be-
tween basal IL-6 levels and ERK phosphorylation in peri-
toneal M-DM from patients with cirrhosis [10], and
point to significant differences between ALC-C and
HCV-C patients as regards the primed status at baseline.
Discussion
Clinical research in human diseases is largely based on
samples obtained by surgical or aggressive procedures
from extremely ill patients. This implies the use of con-
venience samples of limited size rather than larger sam-
ples drawn at random from the population. Therefore,
the main limitation of this type of study on the immune
status in cirrhotic ascites is the nature and size of the
sample. To minimize this limitation we processed con-
secutive samples obtained from cirrhotic patients from
two different institutions during a three year period. A
robust statistical test was used to ensure that the
observed differences were significant. Nevertheless, this
Figure 2 Cytokine levels produced by Monocyte-Derived Macrophages from ascites of patients with HCV-C or ALC-C. A) Cytokine
concentration was measured by ELISA in ascites from patients with HCV-C (n = 15) or ALC-C (n = 30) and results were related to M-DM present in
ascites. B) M-DM present in ascites were isolated as indicated in Methods and the cytokine concentration was measured by ELISA in cell culture
supernatants after 24 h. Results are expressed in pg/106 M-DM and represented as box plot. Circles out of the boxes correspond with outliers.
Mann–Whitney U test:* P < 0.05, ** P < 0.01.
Table 3 Monocyte-Derived Macrophages response to
in vitro stimulation
Cytokines Etiology Fold activation
LPS ODN C. albicans
TNF-α ALC-C 89.26 (204.5) a 0.89 (1.7) 170.92 (374.6) a
HCV-C 97.61 (163.9) a 2.42 (4.9) 4334.96 (595.4) a
IL-6 ALC-C 2.73 (3.5) a 0.84 (5.8) 3.35 (10.4) a
HCV-C 5.97 (19.6) *,a 1.26 (7.2)*,a 5.68 (37.2) *,a
IL-10 ALC-C 9.06 (6.2)a 0.77 (0.6) 13.7 (24.5) a
HCV-C 11.33 (13.9) a 1.4 (2.6) *,a 223.4 (45.3) a
IL-12 ALC-C 1.75 (3.4) a 2.1 (8.4) 3.7 (6.6) a, *
HCV-C 3.15 (4.8) 6.6 (17.4) 1.93 (1.1)
IL-1β ALC-C 20.21 (63) a 1.5 (10) 46.85 (135.6) a
HCV-C 10.89 (24.7) a 2.11 (2.73) 15.4 (28.5) a
Results are expressed as median (interquartile range). Mann–Whitney U test:
* P < 0.05 between ALC-C and HCV-C; Wilcoxon signed-rank test: a P <0.05
between control and treatments.
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results observed in samples of convenience can be gen-
eralized to the larger population. Herein we show first,
that compared with ALC-C, HCV-C associated ascites
contains a significantly higher number of leukocytes, al-
though these findings did not match the cellular distri-
butions observed in the peripheral blood. This indicates
that the absolute cell number and population distribu-
tion of peritoneal leukocytes in cirrhotic ascites varies
with the underlying cause and does not mirror the situ-
ation in peripheral blood. In this regard it is important
to remark that the majority of studies on immune cells
in human cirrhosis have been performed in blood sam-
ples, mainly due to the difficulty involved in obtaining
and managing ascites [11,12] and in to a lesser extent, in
liver biopsies [13,14]. Thus, it is interesting to further
explore the ascites in order to extrapolate data on
immune cells from the above three types of samples
to better understand the mechanisms underlying the
Figure 3 ERK1/2 phosphorylation levels in Monocyte-Derived
Macrophages from ascites of patients with HCV-C or ALC-C.
A) Representative immunoblots for p-ERK1/2 of peritoneal M-DM
from patients with HCV-C (n = 4) or ALC-C (n = 12) at baseline and
following LPS treatment. β-actin was measured as loading control.
B) Immunoblots were quantified and the average ± SEM ratios of
phosphorylation are represented as bar graphs referred to β-actin.
Wilcoxon signed-rank test: # P < 0.05, ###P < 0.001, between control
(normalized as 1) and treatments. Mann–Whitney U test: *P < 0.05,
between ALC-C and HCV-C.
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predict the risks and outcomes of apply the appropri-
ate treatments.
Furthermore the findings also reveal that leukocyte
migration towards the peritoneal cavity is not a passive
process induced by hemodynamic anomalies associated
to cirrhosis, like portal hypertension, but more of an ac-
tive chemoattractant-induced process, recruiting leuko-
cytes not only from blood vessels, but also from
impaired lymphatic drainage [15]. Moreover the higher
number of leukocytes in ascites from HCV-C vs. ALC-C
group resulted from increases in the T lymphocyte,
PMN and monocyte cell subpopulations. This suggests
that a specific differential pattern of chemoattractant
stimuli must be involved in the recruitment of each par-
ticular cell population, depending on the microbial stim-
uli involved in the cirrhosis etiology. In this regard, it
has been shown that the expression of CCR1, -2, -5 and
CXC-1 is induced in patients with chronic liver diseases,
so that intrahepatic increases of CCL3-5 and IL-8chemokines would be involved in recruiting not only
monocyte/macrophages but also other immune cell
populations [16,17].
Our results also showed that ascites from HCV-C
patients exhibits a significantly lower concentration of
IL-12 pro-inflammatory cytokine and a significant higher
amount of the anti-inflammatory cytokine IL-10 com-
pared with the ALC-C group, suggesting a predominant
Th2/Treg profile in the pathogenesis of advanced HCV-
C. Indeed, it has been described that HCV by itself
induces intrahepatic Tr1 cells [18], expands peripheral
Treg in patients with normal aminotransferases [11] and
affects dendritic cell function, switching the cytokine
profile towards a suppressive phenotype of IL-10 and
transforming growth factor beta predominance, prevent-
ing cell maturation and inhibiting the allostimulating
capacity [19]. However, when cytokine levels were com-
pared with the number of M-DM contained in ascites of
these patients, or secreted in vitro by isolated peritoneal
M-DM, apart from differences in IL-12, the concentra-
tion of IL-6 and TNF-α also significantly differed be-
tween both groups of patients. Furthermore, this fact
was associated with lower baseline ERK1/2 phosphoryl-
ation than observed in the ALC-C group. Four conclu-
sions can be drawn from these findings. First, these
results confirm and extend the positive correlation
established between basal IL-6 levels and ERK phosphor-
ylation in peritoneal M-DM from patients with cirrhosis
[10]. Second, they indicate that M-DM are “differently
primed” by the in vivo pathophysiological environment
and preserve their inflammatory differentiation profile
for at least 24 h, being more pro-inflammatory in the
case of ALC-C. This “alert state” could provide an ad-
vantage for preventing the development of SBP in inter-
mittent events of intestinal bacterial translocation in
ALC-C patients. Third, they confirm the predominantly
immune inhibited status of M-DM in the end-stages of
HCV-induced hepatic damage compared with ALC-C
[20], which may be intended to prevent immune-
mediated decompensation. Fourth, the drop of signifi-
cant differences in IL-10 levels with respect to M-DM
strongly suggests that other immune cells are contribut-
ing to the total amount of this anti-inflammatory cyto-
kine in ascites of the HCV-C group, especially regulatory
Th subpopulations. However, this does not mean that
M-DM from HCV-C are functionally exhausted or
endotoxin-tolerant as described [21], since they are able
to further respond to stimulation by several PAMP ago-
nists. In fact, the relative increase of IL-6 secretion and
ERK1/2 phosphorylation in isolated M-DM stimulated
by LPS was significantly higher in HCV-C than in ALC-
C patients. The same results were obtained for IL-6 se-
cretion induced by ODN and C. albicans, and IL-10
induced by ODN from the HCV-C group. The above
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susceptibility to ligands of PRRs in the M-DM present in
ascites from both types of cirrhotic patient. Supporting
this hypothesis, the clear up-regulation of TLRs has
been reported in specimens from patients with HCV in-
fection [22,23] and ALC-induced liver damage (reviewed
in [24]).
SBP caused by translocation of intestinal bacteria and
their products such as LPS or bacterial DNA is one of
the main life-threatening complications of cirrhosis [25].
Faced with this condition, the quality and intensity of
the peritoneal immune response seemingly plays a cru-
cial role in the prognosis of these compromised patients.
The lower inflammatory profile of ascites of the HCV-C
compared with alcoholic etiology could also be the result
of the hypothetically lower frequency of intestinal bac-
terial translocation in HCV-C patients. Our results indi-
cate the need for additional studies with a larger clinical
sample to answer the question as to whether or not the
difference in the MD-M peritoneal inflammatory status
could influence the clinical outcome of patients beyond
six months or the tolerance of a transplanted liver.
Conclusions
This study shows for the first time, that the concentra-
tion of T lymphocyte, PMN and monocyte subpopula-
tions in ascites of patients with HCV-C is higher than
that of patients with ALC-C, while no significant differ-
ences exist in peripheral blood. This indicates the lack of
correlation between circulating white blood cell numbers
and peritoneal leukocytes in cirrhotic ascites. The study
provides important information on some differential
characteristics of cirrhotic peritoneal M-DM that will
allow extrapolation to previous data obtained in periph-
eral blood and liver biopsies. This will contribute to a
better understanding of the mechanisms underlying the
pathogenesis of liver damage leading to decompensated
cirrhosis of differing etiologies. Thus, HCV etiology is
associated with a predominant immune inhibitory status
in ascites and isolated peritoneal M-DM unlike the cir-
rhosis induced by alcohol. A better knowledge of the cel-
lular and molecular pathways of M-DM activation in
cirrhosis could contribute to the design of further stud-
ies to identify potential prognostic and/or therapeutic
targets for liver fibrosis of different etiologies.
Methods
Patients
Patients were admitted at the Liver Unit of Hospital
General Universitario, Alicante, Spain, or at the Liver
Transplant Unit of Hospital Universitario Virgen de la
Arrixaca, Murcia, Spain. Cirrhosis was diagnosed by
histology or by clinical, laboratory, and/or ultrasono-
graphic findings. Exclusion criteria were the presence ofa culture-positive blood or ascites, an ascites poly-
morphonuclear (PMN) count equal or higher than 250/μl
[26], signs or symptoms of systemic inflammatory response
syndrome [27], upper gastrointestinal bleeding, hepatocel-
lular carcinoma fulfilling Milan criteria [28] and/or portal
thrombosis, previous liver transplantation, transjugular
intrahepatic portosystemic shunt, alcoholic hepatitis, age
older than 80 or younger than 18, etiology other than
alcohol intake or HCV infection and refusal to partici-
pate in the study. The ethics committees (Comité Ético
de Investigación Clínica del Hospital General de Alicante
and Comité de Bioética de la Universidad de Murcia)
approved the study protocol and all patients gave
informed consent to be included in this study. A conveni-
ence sample of 61 consecutive patients who fulfilled all
inclusion/exclusion criteria and who signed the informed
consent were included in the study.Blood and ascites samples
Peripheral blood and ascites were collected from
patients with cirrhosis requiring a large-volume paracen-
tesis at admission.
Blood was obtained for routine haematological, bio-
chemical and coagulation studies. Simultaneously, a
large-volume paracentesis was performed on all patients
at admission in aseptic conditions following the usual
procedures to obtain ascites [29]. All patients received
intravenous albumin after paracentesis (8 g/l of ascites)
as routine protocol, if the volume of ascites evacuated
was greater than 5 liters. Samples for routine biochem-
ical study and PMN counts were obtained. Total protein,
albumin, leukocyte and PMN counts were performed in
all ascites specimens. Both blood and ascites were inocu-
lated at bedside in aerobic and anaerobic blood culture
bottles, 10 ml each [30].Flow cytometry analysis
Ascites samples were centrifuged at 500 × G, the super-
natant was collected for cytokine detection and cells
were collected and washed in PBS, and then resus-
pended in DMEM (GIBCO Invitrogen, Paisley, UK).
Cells from ascites were stained with monoclonal anti-
bodies and analyzed by flow cytometry to determine cell
types. Antibodies were mouse anti-human CD14-FITC
(eBioscience, San Diego, CA), CD3-FITC, CD19-PE Cy5,
CD14-PE and CD16-PE Cy5 (BD-Pharmingen, San
Diego, CA). The mouse IgG1-PE, mouse IgG1-FITC,
mouse IgG1-PE Cy5, mouse IgG2b-FITC and mouse
IgG2b-PE antibodies used as isotype controls were from
BD-Pharmingen. In brief, 0.3 × 106 cells in a volume of
100 μl were stained with 5 μl of the corresponding
monoclonal antibodies and incubated in the dark on ice
fixed in solution of lysis (Becton Dickinson, San José,
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4°C in the dark until data acquisition.
Flow cytometry analyses were performed on three-
color fluorescence Epics XL (Beckman Coulter) using
Cytomics RXP analysis software. 50,000-100,000 gated
events were acquired and analyzed. Leukocytes were
gated based on FCS vs. SSC (Forward vs. Side Scatter)
on a lineal scale. Then, leukocyte subpopulations were
gated on the base of morphology and CD14+ expression
for peritoneal M-DM, CD3+ expression for T lympho-
cytes, CD19+ expression for B lymphocytes and CD3-
CD14-CD19-CD16+ expression for NK cells.
Isolation and stimulation of M-DM
Cells were then seeded for panning at a ratio of 0.2 ×
106 M-DM/well in 96-well plates for ELISA, or 1-2 ×
106 M-DM/well in 6-well plates for immunoblotting,
according to the percentage of CD14+ cells determined
by flow cytometry. After an overnight incubation at 37°C
in DMEM containing 10% fetal bovine serum and 1%
penicillin/streptomycin (complete culture medium), cells
were washed with complete culture medium to eliminate
non-adhered cells, including lymphocytes. The purity of
the M-DM in cell culture was more than 95%. Then
M-DM were maintained for 3 hours in serum starvation
conditions (2% FBS) and treated for 15 minutes with LPS
(E. coli serotype 0111.B4, Sigma Aldrich Co, Saint Luis,
Missouri, USA) for immunoblotting analysis of cell lysates,
or directly with 0.1 μg/ml LPS, heat-killed C. albicans
SC5314 strain at ratio 1/5 cell/yeasts and synthetic phos-
phorothioate oligodeoxynucleotides (ODN) (1 μg/ml) pre-
senting the following sequence 5’ TGA CTG TGA ACG
TTC GAG ATG A 3’ (TriLink BioTechnologies, San
Diego, CA) for ELISA. After 24 hours of incubation, cell
culture supernatants were collected for cytokine detection.
ELISA
Ascitic fluid and cell culture supernatants were assayed by
ELISA kits for TNF-α, IL-1β, IL-6, IL-10 and IL-12. The
assay was performed in triplicate following the manufac-
turer’s instructions (©R&D Systems Inc., Minneapolis,
USA). The absorbance in each well was measured with a
microplate reader at 450 nm and corrected at 570 nm.
Cellular lysates and immunoblotting
Protein extracts were obtained and treated as described
elsewhere [31]. Primary antibodies against phosphorylated
ERK1/2 (Thr202/Tyr204) and β-actin (Sigma Aldrich Co,
Saint Luis, Missouri, USA) were used before incubation
with the corresponding HRP-conjugated secondary anti-
body. The activity of membrane-bound peroxidase was
detected by using an enhanced chemiluminescent detection
method (Enhanced ChemiLuminescence system, ©Amersham
Pharmacia Biotech; Piscataway, NJ, USA). Protein bands werequantified by densitometry using Scion Image software and
expressed relative to β-actin.
Statistical analysis
Categorical variables are reported as frequency or per-
centages. Continuous variables are reported as median
and interquartile range (IQR) and are graphically repre-
sented as box diagrams, where the top and bottom of
the box are the 25th and 75th percentile (the lower and
upper quartiles, respectively), and the band inside the
box is the 50th percentile (the median), the end of the
whiskers represent the lowest datum still within 1.5 IQR
of the lower quartile, and the highest datum still within
1.5 IQR of the upper quartile. The observations consid-
ered as outliers are shown as circles outside the boxes.
Statistic differences were analyzed using the Mann–
Whitney U test or Wilcoxon signed-rank test. All
reported P values are two-sided, and P values lower than
0.05 were considered to indicate statistical significance.
All calculations were performed using the SPSS 15.0
software (Chicago, IL, USA).
Reporting of the study conforms to STROBE and
EQUATOR guidelines [32].
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